Kiora Pharmaceuticals Inc financial data

Symbol
KPRX on Nasdaq, KPHMW on OTC
Industry
Pharmaceutical Preparations
Location
332 Encinitas Boulevard, Suite 102, Encinitas, CA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
EYEGATE PHARMACEUTICALS INC (to 11/4/2021)
Latest financial report
10-Q - Q2 2024 - Aug 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.1K % +293%
Debt-to-equity 37.3 % -36.9%
Return On Assets 11.3 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.97M shares -59%
Common Stock, Shares, Outstanding 2.97M shares -57%
Entity Public Float 4.76M USD -22.1%
Common Stock, Value, Issued 267K USD +287%
Weighted Average Number of Shares Outstanding, Basic 4.17M shares +1041%
Weighted Average Number of Shares Outstanding, Diluted 4.17M shares +1041%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 20K USD
Research and Development Expense 4.6M USD +14.8%
General and Administrative Expense 5.13M USD -28.5%
Operating Income (Loss) 2.64M USD +3.35%
Nonoperating Income (Expense) 650K USD +1584%
Net Income (Loss) Attributable to Parent 3.2M USD +15%
Earnings Per Share, Basic 5.45 USD/shares +92.6%
Earnings Per Share, Diluted 5.31 USD/shares +92.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.58M USD -17.3%
Accounts Receivable, after Allowance for Credit Loss, Current 1.34M USD
Assets, Current 31.8M USD +253%
Property, Plant and Equipment, Net 63.5K USD +41.5%
Operating Lease, Right-of-Use Asset 82.3K USD +63.9%
Intangible Assets, Net (Excluding Goodwill) 8.8M USD -18%
Goodwill 0 USD
Other Assets, Noncurrent 32.1K USD -0.75%
Assets 40.8M USD +105%
Accounts Payable, Current 269K USD +105%
Employee-related Liabilities, Current 678K USD -35.5%
Accrued Liabilities, Current 1.35M USD -3.85%
Liabilities, Current 1.66M USD -12.1%
Deferred Income Tax Liabilities, Net 779K USD +13.1%
Operating Lease, Liability, Noncurrent 40.2K USD
Liabilities 7.71M USD +23.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -246K USD -8.8%
Retained Earnings (Accumulated Deficit) -136M USD +2.3%
Stockholders' Equity Attributable to Parent 33.1M USD +143%
Liabilities and Equity 40.8M USD +105%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 13.6M USD
Net Cash Provided by (Used in) Financing Activities 15.2M USD +2871%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 150M shares +200%
Common Stock, Shares, Issued 2.97M shares -57%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 28.8M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.58M USD -17.3%
Deferred Tax Assets, Valuation Allowance 33M USD +11.6%
Deferred Tax Assets, Gross 34.5M USD +9.8%
Operating Lease, Liability 82.3K USD +111%
Lessee, Operating Lease, Liability, to be Paid 92.8K USD +137%
Property, Plant and Equipment, Gross 14.4K USD -91.7%
Operating Lease, Liability, Current 42.1K USD +7.99%
Lessee, Operating Lease, Liability, to be Paid, Year Two 13.9K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 27.1K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 10.5K USD +5873%
Lessee, Operating Lease, Liability, to be Paid, Year Three 13.9K USD
Deferred Tax Assets, Operating Loss Carryforwards 26M USD +13.9%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 11K USD
Operating Lease, Payments 55.8K USD +0.07%
Additional Paid in Capital 169M USD +10.5%
Depreciation, Depletion and Amortization 4.87K USD -51.7%
Deferred Tax Assets, Net of Valuation Allowance 1.52M USD -18.8%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%